Tandem Transplant

Tandem hematopoietic stem cell transplantation (planned autologous tandem HCT, or autologous followed by allogeneic reduced‑intensity HLA‑identical sibling transplant) is covered for select malignancies—notably newly diagnosed or responsive multiple myeloma, relapsed or cisplatin‑refractory testicular germ cell tumor, and specified high‑risk neuroblastoma stages—per the policy criteria. Coverage is limited to transplant‑eligible patients without major organ dysfunction or severe comorbidities (e.g., total bilirubin ≤2 mg/dL, INR ≤1.6 unless on oral anticoagulants, LVEF ≥45%, FEV1 >50% or DLCO >60%, Karnofsky/Lansky ≥70 or ECOG ≤2, no uncontrolled/disseminated infection); HLA‑compatible unrelated donor allogeneic transplants are reviewed case‑by‑case and sibling allogeneic transplants must use reduced‑intensity conditioning.

"Newly diagnosed or responsive multiple myeloma (MM)."